A transfectant mosaic xenograft model for evaluation of targeted radiotherapy in combination with gene therapy in vivo.

A transfectant mosaic xenograft model for evaluation of targeted radiotherapy in combination with gene therapy in vivo. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

A transfectant mosaic xenograft model for evaluation of targeted radiotherapy in combination with gene therapy in vivo. Abstract Text:

Robert J Mairs,Susan C Ross,Anthony G McCluskey,Marie Boyd,

For gene therapy to be efficacious in the treatment of cancer, therapeutic transgenes must be limited in their expression to tumor cells and must be expressed at sufficiently high transcriptional levels. Moreover, the inadequacy of gene delivery must be overcome by induction of toxicity to neighboring nontargeted cells. Combining targeted radionuclide therapy with gene therapy using human telomerase promoters has shown promise in these respects, and the efficacy of this scheme has been assessed in vitro using transfectant mosaic tumor spheroids. To enable the evaluation of targeted radiotherapy combined with gene transfer in vivo, we have developed a transfectant mosaic xenograft (TMX) model. METHODS: Human telomerase promoters were used to drive expression of the noradrenaline transporter (NAT) transgene in 2 human cell lines (UVW and EJ138). Promoter activity was assessed in xenografts in nude mice by determination of the uptake of the radiopharmaceutical (131)I-metaiodobenzylguanidine ((131)I-MIBG) and by measurement of tumor growth. The efficacy of (131)I-MIBG treatment was also assessed in TMXs to determine the delay in growth of tumors composed of various proportions of NAT-expressing cells-a likely clinical scenario after gene delivery in vivo. RESULTS: In terms of induction of the capacity for active uptake of (131)I-MIBG and the resultant inhibition of tumor growth in vivo, both telomerase promoters (hTR and hTERT) were similar in potency to the CMV (cytomegalovirus) promoter as controlling elements for the expression of the NAT transgene. In TMXs derived from UVW and EJ138 cells, (131)I-MIBG uptake was proportional to NAT gene expression (r(s) = 0.910, P < 0.001 for UVW; r(s) = 0.971, P < 0.001 for EJ138). Inhibition of the growth of these tumors correlated with the fraction of NAT-transfected cells (r(s) = 0.910, P < 0.001 for UVW; r(s) = 0.971, P < 0.001 for EJ138), and substantial tumor growth delay was observed when 5% of the xenograft was composed of NAT-positive cells. CONCLUSION: TMXs constitute a suitable model to measure the efficacy of cancer gene therapy strategies when <100% of the tumor mass can be targeted to express the therapeutic transgene.

A transfectant mosaic xenograft model for evaluation of targeted radiotherapy in combination with gene therapy in vivo. Publishing Authors By Initials

RJ Mairs,SC Ross,AG McCluskey,M Boyd,

For similar surgical procedures, operative: transplantation: transplantation, heterologous research abstracts see: surgical procedures, operative: transplantation: transplantation, heterologous research

PUBMED ID PMID:

MEDLINE DATE:

A transfectant mosaic xenograft model for evaluation of targeted radiotherapy in combination with gene therapy in vivo. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: Journal of nuclear medicine : official publication

VOLUME: 48

Page Numbers: 1519-26

Journal Abbreviation: J. Nucl. Med.

ISSN: 0161-5505

DAY: 17

MONTH: 08

YEAR: 2007

A transfectant mosaic xenograft model for evaluation of targeted radiotherapy in combination with gene therapy in vivo. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 217410

A transfectant mosaic xenograft model for evaluation of targeted radiotherapy in combination with gene therapy in vivo. Keywords Mesh Terms:

KEYWORDS: Transplantation, Heterologous

MESH TERMS: therapeutic use

Chemical & Substance for Abstract: A transfectant mosaic xenograft model for evaluation of targeted radiotherapy in combination with gene therapy in vivo. Information

Substance Name: 3-Iodobenzylguanidine

Registry Number: 77679-27-7

Grant and Affiliation Information for A transfectant mosaic xenograft model for evaluation of targeted radiotherapy in combination with gene therapy in vivo.

AFFILIATION: Targeted Therapy Group, Division of Cancer Science and Molecular Pathology, Glasgow University, Cancer Research United Kingdom Beatson Laboratories, Glasgow, United Kingdom.

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: J Nucl Med

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

A transfectant mosaic xenograft model for evaluation of targeted radiotherapy in combination with gene therapy in vivo Related Publications

• 982.
• A transfectant mosaic xenograft model for evaluation of targeted radiotherapy in combination with gene therapy in vivo.
• Accuracy of high-resolution peripheral quantitative computed tomography for measurement of bone quality.
• Attitudes toward performance of endoscopic colon cancer screening by family physicians.
• Automatic segmentation of cortical and trabecular compartments based on a dual threshold technique for in vivo micro-CT bone analysis.
• Beyond the absorption-limited nonlinear phase shift with microring resonators.
• Bulk and dispersed aqueous phase behavior of phytantriol: effect of vitamin E acetate and F127 polymer on liquid crystal nanostructure.
• Calix[4]arene-linked bisporphyrin hosts for fullerenes: binding strength, solvation effects, and porphyrin-fullerene charge transfer bands.
• Chimeric constructs endow the human CFTR Cl- channel with the gating behavior of murine CFTR.
• Complete 1H, 13C and 15N NMR assignment of tirapazamine and related 1,2,4-benzotriazine N-oxides.
• Complex orthodontic treatment using a new protocol for the Invisalign appliance.
• Coumarins from Apium graveolens seeds.
• Design of a tunable time-delay element using multiple gain lines for increased fractional delay with high data fidelity.
• Eccrine syringofibroadenoma with co-existent squamous cell carcinoma.
• Enhanced immune reconstitution by sex steroid ablation following allogeneic hemopoietic stem cell transplantation.
• Enhancement of two-photon emission in photonic crystals.
• Expression cloning identifies transgelin (SM22) as a novel repressor of 92-kDa type IV collagenase (MMP-9) expression.
• Fossilized high pressure from the Earth's deep interior: the coesite-in-diamond barometer.
• Heterogenic loss of the wild-type BRCA allele in human breast tumorigenesis.
• Illicit use of specific prescription stimulants among college students: prevalence, motives, and routes of administration.
• Intramolecular electron transfer in the dihaem cytochrome c peroxidase of Pseudomonas aeruginosa.
• Mitral valve papillary fibroelastoma: surgical considerations.
• Modeling the reduction of hydrogen peroxide by glutathione peroxidase mimics.
• PTO pyramid.
• Plasticity in urokinase-type plasminogen activator receptor (uPAR) display in colon cancer yields metastable subpopulations oscillating in cell surface uPAR density--implications in tumor progression.
• Regulation of matrix metalloproteinase gene expression.
• Selection of a dye for use in semen transport studies in the cow.
• Theoretical study of the thermolysis of beta-hydroxyl aldehydes.
• Turning "smoking man" images around: portrayals of smoking in men's magazines as a blueprint for smoking cessation campaigns.
• Ubiquitin conjugating enzymes participate in polyglutamine protein aggregation.